B
Bull
Bull · 25%URGN
$7.21
Precio del escenario
$43.090
-0.526 (-1.22%)Al cierre
Loading chart…
- High
- 44.860
- Open
- 43.170
- VWAP
- 43.32
- Vol
- 749.04K
- Mkt Cap
- 697.98M
- Low
- 42.000
- Amount
- 32.45M
- EV/EBITDA, TTM
- 651.89
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
AI analysis of Urogen Pharma Ltd (URGN)
buyUrogen Pharma Ltd is a good buy right now due to its significant revenue growth, with Q2 2026 revenue reported at $72.5 million, a 73% increase sequentially, and a narrowing net loss of $14.4 million. The stock is currently priced at $43.62, well below the average analyst target of $60, suggesting a potential upside of 37.5%. However, the current RSI of 25.308 indicates the stock is oversold, which may present a buying opportunity despite recent volatility.
Analyst Ratings (4)
-6.59% downside
Buy
3 Buy
1 Hold
0 Sell
Current: 43.09
Mínimo
31.00
Promedio
40.25
Máximo
55.00
Oppenheimer
Outperform
$60
2026-08-06
Oppenheimer
2026-08-06
Precio objetivo
$60
Outperform
H.C. Wainwright
Buy
$75
2026-08-06
H.C. Wainwright
2026-08-06
Precio objetivo
$75
Buy
Guggenheim
Buy
$58
2026-08-06
Guggenheim
2026-08-06
Precio objetivo
$58
Buy
TD Cowen
Buy
$60
2026-08-05
TD Cowen
2026-08-05
Precio objetivo
$60
Buy
Guggenheim
Buy
$42
2026-07-21
Guggenheim
2026-07-21
Precio objetivo
$42
Buy
Métricas de valoración
The current forward P/E ratio for Urogen Pharma Ltd (URGN) is 0.00, compared to its 5-year average forward P/E of -4.35.
Alphio AI Price Scenarios for URGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding URGN
Cronología de eventos
Noticias
8.508-20NASDAQ.COMUroGen Pharma Enters Investment and License Agreement with IntraGel
8.508-20PRnewswireIntraGel and UroGen Enter Strategic Investment Agreement
8.508-20NewsfilterIntraGel Secures $7 Million Investment from UroGen for TumoCure Development
- 7.508-20Newsfilter
UroGen Partners with IntraGel for Oncology Product Development
2.008-06NASDAQ.COMUroGen Pharma Stock Surpasses Analyst Target Price
URGN FAQ — answered by Alphio AI
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Urogen Pharma Ltd is a good buy right now due to its significant revenue growth, with Q2 2026 revenue reported at $72.5 million, a 73% increase sequentially, and a narrowing net loss of $14.4 million. The stock is currently priced at $43.62, well below the average analyst target of $60, suggesting a potential upside of 37.5%. However, the current RSI of 25.308 indicates the stock is oversold, which may present a buying opportunity despite recent volatility.
4 analysts cover URGN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 40.25.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.